Purpose Diagnosis of solitary pulmonary nodule (SPN) is an important public health issue and 18 F-FDG PET/CT has proven to be more effective than CT alone. Pre-test risk stratification and clinical presentation of SPN could affect the diagnostic strategy. A relevant issue is whether thoracic segmental (s)-PET/CT could be implemented in patients with SPN. This retrospective multicenter study compared the results of FDG whole-body (wb)-PET/CT to those of s-PET/CT. Methods
Introduction
The mean prevalence of solitary pulmonary nodule (SPN) is relatively high (13-33%), but with a low prevalence of lung cancer (<2%) [1] . Its characterization represents an important public health issue, since lung cancer is the leading cause of cancer death, despite possibility of cure and a favorable 5-year survival rate after surgical resection at an early stage [2, 3] .
Computed tomography (CT) is an excellent diagnostic tool, albeit affected by a suboptimal specificity. Contrast-enhanced CT may improve specificity, but the increasing dosimetry, although significantly reduced with modern technologies, is questionable in a highly benign context [4, 5] and it is not recommended where positron emission tomography (PET)/ CT is an available alternative [1] . 18 F-fluorodeoxyglucose (FDG) PET/CT has proven to be more effective than CT [6, 7] and is fully integrated into SPN clinical guidelines [1, 8, 9] .
The accurate assessment of risk before diagnostic imaging is a crucial issue in medicine and management of patients with SPN relies on likelihood of disease [1, 8, 9] . In patients with low to moderate pre-test probability of malignancy, the American College of Chest Physicians recommends the characterization of SPN (>8 mm in diameter) by PET/CT, whereas staging is reserved when malignancy is highly probable or confirmed [8] . It should be noted that there is a low prevalence of malignancy and an even lower prevalence of metastases at clinical presentation in SPN [1, 10, 11] . Recently, concerns have emerged for rising healthcare costs and the increasing medical exposure to ionizing radiation associated with hybrid imaging [12, 13] . In this regard, the first priority of the 2016-2020 International Commission on Radiological Protection (ICRP) Strategic Plan is to improve radioprotection, i.e. to reduce patient dose while maintaining diagnostic information [14] .
FDG-PET/CT procedure guidelines consider limited-area tumor imaging only for some indications, such as follow-up examinations [15] or when critical abnormalities are likely to be localized in a known region (e.g., SPN or probable lung cancer) [16] . However, concerns exist on the possible disadvantage of not staging the entire body [16] . Segmental (s-PET/ CT), i.e. limited to a thoracic acquisition, could be a costeffective approach in SPN [17] [18] [19] but the absence of studies leaves several questions unanswered [20] . The aim of this retrospective multicenter study was to compare the results of thoracic s-PET/CT to those of wb-PET/CT in a large cohort of patients with SPN in order to assess: (a) the feasibility of s-PET/CT without a significant loss in clinical information, (b) the possibility to identify patients in whom wb-PET/CT is necessary, and (c) the advantages and disadvantages of s-PET/CT in SPN.
Material and methods

Study approval and data collection
The study protocol was approved by Veneto Institute of Oncology in Padova (Italy) on September 2016 (nr. 0016), in accordance with Italian Institutional Legacy. Thirteen Italian imaging centers experienced in FDG-PET/CT in lung cancer were invited to participate [21] . Each patient signed a written informed consent for the execution of PET/CT and for anonymous publication of disease-related information. All centers provided a list of anonymous cases in expressly created dedicated Excel datasheets. After combining all received datasheets, reports were generated for each variable to identify data inconsistencies. Through regular communication with all sites, resolution of all identified anomalies was achieved before analysis. Finally, the database was built, and the final data set was produced for the current analysis.
Study population
From September 2016 to May 2017, FDG-PET/CT scans of 502 consecutive patients with SPN, performed between January 2013 and December 2014, were retrospectively reviewed and collected. Patients with one or more SPN previously identified by CT images, defined as lung nodule with a size <3 cm, with no associated atelectasis or adenopathy, and sent to PET/CT for the characterization of the nodule/nodules were included. Patients with prior cancer history and those candidates to PET/CT for the staging of lung cancer were excluded. Patients were stratified in low (<5%), intermediate (5-65%) and high (>65%) risk category using the Brock model of pre-test probability of lung malignancy [8, 22] . A further category was derived from the British Thoracic Society (BTS) guidelines [1] , which are more recent and extend the low probability up to 10%.
PET/CT imaging
PET/CT images were acquired in all centers by using a standard comparable protocol with integrated 3-D mode PET/CT systems, from the base or top of the skull to mid-thigh (wb-PET/CT) starting 60 min after tracer administration. All patients fasted for at least 6 h prior to imaging, and blood glucose levels were < 180 mg/dL at the time of tracer injection. All patients were instructed to avoid talking, chewing or any muscular activity before acquiring PET/CT scan. Attenuation correction was performed using CT images. CT and PET images were matched and fused into transaxial, coronal, and sagittal images. Two experienced nuclear physicians reviewed PET/ CT scan, partially blinded and based on visual analysis to identify the areas of disease. A positive PET scanner was defined in the presence of significant FDG uptake in the SPN. Moreover, intra and extra-thoracic sites were defined in the presence of significant FDG uptake outside the areas of physiological biodistribution.
FDG uptake in SPN was assessed: (1) visually, using a 4-point scoring system (4PS), whereby 1 = absent, 2 = mild, 3 = moderate and 4 = intense [1] ; (2) by a semi-quantitative analysis calculating maximum body-weighted standardized uptake value (SUVmax) in SPN and the ratio between SUVmax in SPN and SUV-mean in mediastinal blood pool (SUV-ratio), by isocontour volume of interest in the SPN and mediastinal blood pool [21] . In patients with more than one nodule, only the Brock highest-risk nodule was evaluated.
The transformation of the CT dose-length product (DLP in cm × mGy) and FDG dose (in MBq) in effective dose (ED, in mSv) was made according to ICRP [23] .
Standard of reference
Final diagnosis was established by histopathology or imaging data at follow-up. The diagnosis of malignancy was made by: (1) histopathological analysis of surgical specimen or histology obtained by needle biopsy and (2) a significant increase in SPN diameter (≥25%) and/or number of pulmonary nodules at CT studies during follow-up [24] . Nodules were considered benign on histopathology or those that during a follow-up of ≥24 months did not change or were spontaneously resolved. In all other cases, they were defined indeterminate. Incidental findings were defined as foci of unexpected FDG uptake regardless of the presence or absence of tracer avidity in the SPN.
Comparison between wb-PET/CT and s-PET/CT s-PET/CT was retrospectively defined as the beds of the wb-PET/CT covering the chest from the first costovertebral articulation to the entire costodiaphragmatic sinuses. The ratio between number of beds in s-PET/CT and wb-PET/CT was the basis to estimate the temporal relationship between the two modalities. Based on the time-dose equation, two alternative s-PET/CT methodologies were compared: full FDG dose (first option), allowing a time reduction for chest scan only and reduced FDG dose (second option), acquiring s-PET/CT at the same scan-time as wb-PET/CT that leaves the thoracic counts unchanged [15] .
Statistical analysis
Continuous data are expressed as mean ± SD and categorical data as percentage. A commercial statistical software was used (MedCalc®). Differences between continuous data were assessed using unpaired Student's t test. Categorical data were evaluated by chi-square analysis, Fisher exact test, MannWhitney or Wilcoxon test, as appropriate. Receiver operating characteristic curve analysis was used to evaluate the diagnostic performance of variables. Analysis of diagnostic performance was also performed by calculating sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy, with 95% confidence interval (CI). Univariate and multivariate logistic analysis was used to evaluate significant determinants of extra-thoracic metastases. A p value <0.05 was considered statistically significant.
Results
General features of the study population are reported in Table 1 . Based on standard of reference, 180 (36%) patients had malignant disease (94% histologically confirmed), 175 (35%) benign disease (34% histologically confirmed) and 147 (29%) indeterminate lung nodules. Patients were in low, intermediate and high category risk in 15%, 77% and 8%, respectively, and in BTS low-risk in 27%. FDG uptake score was 1 in 29%, 2 in 23%, 3 in 12%, and 4 in 36% of SPN. A significant relationship between FDG uptake score and risk category (chi-square 75, p < 0.0001) was found.
Clinical disease presentation and prediction of distant metastases
Thoracic and extra-thoracic PET/CT findings of the study population are reported in Table 2 . Overall, 436 patients (87%) did not have metastases, 66 (13%) had an FDG uptake suggestive of thoracic metastases (47 lymph node, 12 both lymph node and others, and 7 others) and 13 (3%) had evidence of extra-thoracic metastases (3 both lymph node and others, and 10 only others). All 13 patients with extrathoracic metastases had a thoracic lymph node involvement. The prevalence of extra-thoracic metastases progressively increased from patients with low risk (0%) to those with intermediate (3%) and high (5%) pre-test risk. Six (1%) of these latter patients showed incidental PET findings (rectosigmoid, cervical lymph nodes, sub-diaphragmatic lymph nodes and prostate gland). Patients with extra-thoracic lesions showed higher nodule SUVmax and SUV-ratio, higher 4PS, higher risk probability, larger nodule diameter and higher prevalence of thoracic lesions (Table 3) . At univariate analysis, several variables were significantly associated with the presence of extra-thoracic lesions (Table 4) . When variables significant at univariate analysis were entered at multivariate logistic analysis, only the presence of thoracic lymph node involvement (odd ratio [OR] 8.9; 95% CI 3.5-22.6; p < 0.0001) and nodule SUV-ratio (OR 1.3; 95% C.I.
1.0-1.6; p = 0.04) remained significant. The performance obtained combining these two variables was better than a model based on pre-test Brock probability (area under curve 0.94 ± 0.01 vs. 0.73 ± 0.06, p < 0.0005). Sensitivity, specificity, accuracy, NPV and PPVof this combined model were 100%, 91%, 91%, 100%, and 24%, respectively.
Comparison between wb-PET/CT and s-PET/CT
The comparison between the two modalities is shown in Table 5 . In wb-PET/CT, the external (CT) and internal (PET) radiation components were calculated as 64% and 36% of the total, respectively. The ratio between numbers of beds on s-PET/CT and wb-PET/CT was 0.35. With the first option (i.e. full FDG dose), s-PET/CT compared to wb-PET/ CT could save more than 10 min per scan (5.5 vs. 15.8 min, that is >65% of wb-PET/CT scan-time) and 42% of radiation exposure (7.7 vs. 13.2 mSv, due to decreased external Values are mean ± standard deviation or percentage of patients exposure). With the second option (i.e. low FDG dose), s-PET/CT would need a dose of 101.0 MBq (2.7 mCi), which is 35% of the full dose of 288.6 MBq (7.8 mCi) to obtain the same chest counts and the same scan-time of wb-PET/CT. This option would decrease PET ED from 4.7 to 1.6 mSv (66%) and PET/CT ED from 13.2 to 4.6 mSv (65%).
Discussion
The main finding of this study is that pre-test probability of malignancy affects the extent of disease at the onset of SPN and can guide the diagnostic strategy of PET/CT. In the present study only 13 out of 502 patients (3%) showed extrathoracic metastases and had a significantly higher Brock pretest risk (29% vs. 46%). In patients with low-intermediate pretest probability of malignancy s-PET/CT imaging might be planned in advance, whereas in high-risk patients wb-PET/CT should be directly performed. Therefore, a key point is to identify a priori patients who may have extra-thoracic lesions. A possible role of limited region FDG-PET/CT in screening of patients at high risk of lung cancer has been suggested [25] . In our study, all patients with extra-thoracic metastases had high SPN FDG uptake as well as thoracic lymph node involvement, with NPV of 100%. These data are in agreement with the International Association for the Study of Lung Cancer staging database in which only 0.1% out of 10,410 patients in N0 had distant metastases [26] . Based on the 100% NPV, in absence of a chest lymph node involvement at s-PET/CT, wb-PET/CT can be avoided in 88% of patients, without failing to detect extra-thoracic lesions. On the other hand, in the remaining 12%, wb-PET/CT detected distant metastases in only 22% of patients. A segmental strategy would reduce either radiation dose and administered tracer activity. However, calculation of radiation risk is imprecise and represents extrapolated estimated risk from epidemiologic data to the clinical setting. There is an ongoing debate on the incremental risk to subjects exposed to low diagnostic doses [27, 28] . Given these uncertainties, any ability to reduce radiation without sacrificing diagnostic accuracy would be a positive advancement and consistent with the principle of ALARA. In our study, the reduced exposure, up to 8.6 mSv (65%), as well as the reduced radiosensitive extrathoracic targets due to segmental CT, did not prevent reaching the clinical goal.
The rapidly growing cost of innovative imaging imposes a careful evaluation of its cost-effectiveness [12, 29] . Adopting a segmental strategy could favorably affect productivity. Administering a Bfull^FDG dose (first option), s-PET/CT could save about 10 min/study, i.e. 50% of a wb scan, doubling a laboratory's workflow. Alternatively, the second option to reduce FDG dose may lead to a significant decrease in the tracer cost in addition to the dosimetry. Although the exact estimate of the economic savings is out of the scope of this study, a regional strategy may allow a significant improvement in productivity and health care costs.
The segmental approach has some clinical and practical drawbacks [16, 20] . The first is the inability to complete SPN staging. However, full staging is not always necessary according to clinical SPN guidelines [8] and its requirement should be verified in the individual clinical setting. Although incidental findings on wb-PET/CT may represent a different pathology, the risks of over-diagnosis and over-treatment should be considered [10, 30] . Some disadvantages in terms of practicability of s-PET/CT are due to Bon-the-fly^decisions to complete the study with a subsequent wb-PET/CT acquisition [20] . With modern equipment this approach would require only a few minutes. Also, the choice of the tracer dose just before imaging may produce organizational problems.
Study limitations
The segmental analysis, retrospectively extrapolated from the wb-PET/CT, though with a very strict criterion, is virtual and organizational and logistical problems have not been verified. Failure to homogeneously calibrate a center's imaging systems or centralize the imaging studies could be considered a limitation on the basis that some data (e.g. SUVmax) may be affected by technical and organizational variables. To reduce this effect, we also used SUV corrected for BP activity (SUVratio) to favor a relative internal standardization process. Nevertheless, a perspective study is mandatory to support the clinical application of this new protocol.
Conclusions
Pre-test probability of malignancy can guide the diagnostic strategy of 18 FDG-PET/CT in patients with SPN. In subjects with low-intermediate pretest probability s-PET/CT might be planned in advance, while in those at high risk with thoracic lymph node involvement wb-PET/CT is necessary. A segmental strategy can reduce radiation exposure, scan-time, and might allow individually targeted protocols other than further development of PET indications.
